GRAL vs VCYT: Which Is the Better Buy in 2026?
Last updated September 2026
Short answer
GRAL (GRAIL) and VCYT (Veracyte) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
GRAL vs VCYT: the tie-breaker metrics
Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | GRAL | VCYT | What it tells you |
|---|---|---|---|
| Market cap | $3.56B | $3.49B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -8.08 | 22.29 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 3.25 | 1.94 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 55% of range | 44% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.40 | 2.51 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how GRAL and VCYT affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GRAL and VCYT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GRAL and VCYT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does GRAIL (GRAL) do?
GRAIL, Inc. develops and sells the Galleri multi-cancer early detection (MCED) test, a blood draw that looks for DNA shed by tumors to screen for dozens of cancer types, including many (pancreatic, ovarian, esophageal, liver) that have no standard screening today. The company was originally incubated inside Illumina and became an independent public company after a court-ordered spin-off in 2024, and it now trades on Nasdaq under GRAL. Galleri is sold largely out-of-pocket and through employer and health-system channels while GRAIL pursues regulatory approval and broad insurance reimbursement.
What does Veracyte (VCYT) do?
Veracyte is a US genomic diagnostics company that develops and runs advanced molecular tests used to guide cancer treatment decisions. Its two flagship products drive the business: Decipher, a genomic classifier for prostate cancer, and Afirma, which helps assess indeterminate thyroid nodules to avoid unnecessary surgeries. The company also markets tests in other areas and runs a research platform (Afirma GRID, Decipher studies) built on large proprietary genomic sample databases that act as a competitive moat. Testing revenue is the dominant and fastest-growing part of the mix.
GRAL vs VCYT: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- GRAL drivers: Galleri volume and revenue growth; FDA approval pathway.
- VCYT drivers: Decipher prostate franchise; Afirma thyroid dominance.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. For VCYT, revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately.
GRAL or VCYT: which should you pick?
GRAL vs VCYT: the full fundamentals
GRAL. GRAIL trades on revenue growth and its cash runway rather than earnings, since it is deeply unprofitable while it scales Galleri. The roughly $823 million cash position against a trailing operating cash burn near $290 million a year implies a multi-year runway before any need to raise capital. The high price-to-sales multiple reflects investor expectations tied to FDA approval and future reimbursement, not present profitability.
VCYT. Veracyte is profitable on a GAAP basis with an adjusted EBITDA margin near 31% in Q1 2026, an uncommon profile among growth-stage diagnostics firms. The mid-40s P/E sits well above the broader biotech average, reflecting the market pricing in continued double-digit testing growth. Figures are approximate and drawn from the most recent reported quarter and guidance.
Headline figures (approximate, JULY 2026): GRAL shows revenue (ttm) ~$156M, q1 2026 revenue (yoy) ~$40.8M (+28%), net loss (ttm) ~-$395M, cash & short-term investments ~$823M; VCYT shows revenue (ttm) ~$517M, q1 2026 revenue ~$139M (up ~21% YoY), net income (ttm) ~$66M, 2026 revenue guidance ~$582M to $592M.
The bottom line: GRAL vs VCYT
GRAL and VCYT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GRAL and VCYT exposure against your real portfolio. It is not an investment adviser.
Wondering how GRAL or VCYT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in GRAIL with AI
Connect the broker you already use and ask Walnut's AI how GRAL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between GRAL and VCYT?
+
GRAIL, Inc. Veracyte is a US genomic diagnostics company that develops and runs advanced molecular tests used to guide cancer treatment decisions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is GRAL or VCYT the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, GRAL or VCYT?
+
On forward P/E (as of September 2026), GRAL trades at -8.08x and VCYT at 22.29x, so GRAL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both GRAL and VCYT?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of GRAL vs VCYT?
+
GRAL: GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. The business is concentrated in essentially one product, Galleri, which leaves it exposed to any single negative FDA, clinical, or reimbursement outcome. Competition in multi-cancer detection is intensifying from Exact Sciences (Cancerguard), Guardant Health (Shield), Freenome, and others. Cash burn is heavy (operating cash flow was roughly negative $290 million over the trailing year), and if approval or coverage is delayed, the company may need to raise capital, which could dilute shareholders. The stock is also volatile and trades on a high price-to-sales multiple with no earnings support. VCYT: Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. The stock trades at a premium valuation (P/E in the mid-40s), which amplifies downside if growth decelerates or guidance is missed. Medicare and commercial payer decisions drive a large portion of realized revenue, making pricing and coverage a persistent uncertainty. Larger diagnostics rivals such as Exact Sciences, Guardant Health, and Natera have deeper resources and are expanding into overlapping oncology testing areas. New-test launches and international expansion carry execution and regulatory risk.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GRAL or VCYT; figures are approximate and dated (as of September 2026). Verify current data before investing.